市場調査レポート

商品コード

1563398

モノクローナル抗体の市場規模、シェア、成長分析、供給源タイプ別、生産タイプ別、用途別、最終用途別、地域別 - 産業予測、2024年～2031年

Monoclonal Antibodies Market Size, Share, Growth Analysis, By Source Type, By Production Type, By Application, By End-use, By Region - Industry Forecast 2024-2031

出版日: 2024年09月26日
発行: SkyQuest
ページ情報: 英文 211 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

モノクローナル抗体の世界市場規模は2022年に2,110億米ドルと評価され、予測期間（2024-2031年）のCAGRは11.5%で、2023年の2,352億7,000万米ドルから2031年には5,620億3,000万米ドルに成長する見通しです。

モノクローナル抗体（mAbs）は、特定の白血球をクローン化することで単一細胞系から生成される抗体です。これらの抗体は、その高い特異性と有効性により、医薬品開発や様々な疾患の治療薬として利用されています。慢性疾患の世界の有病率の増加は、今後数年間におけるモノクローナル抗体市場の大幅な成長を促進すると予想されています。さらに、医療研究開発への多額の投資とバイオテクノロジーの進歩により、これらの抗体の需要はさらに高まると予想されます。分子生物学の進歩もモノクローナル抗体市場にプラスに寄与し、その販売と応用を後押しすると予想されます。モノクローナル抗体がヘルスケア、製薬、バイオテクノロジーの各分野で用途を拡大するにつれて、この分野のサプライヤーや開発者にとって新たな機会が生まれつつあります。しかし、この市場は、高い開発コスト、市場投入までの時間の延長、安全性の懸念などの課題に直面しており、これが成長の妨げになる可能性があります。これらの要因は、市場が発展するにつれて、引き続き重要な検討事項となっていくと思われます。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Novartis AG（Switzerland）
Pfizer Inc.（US）
GlaxoSmithKline plc（UK）
Amgen Inc.（US）
Merck & Co., Inc.（US）
Daiichi Sankyo Company, Limited（Japan）
Abbott Laboratories（US）
AstraZeneca plc（UK）
Eli Lilly and Company（US）
Johnson & Johnson Services, Inc.（US）
Bayer AG（Germany）
Bristol Myers Squibb（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Viatris Inc.（US）
Biogen Inc.（US）
Thermo Fisher Scientific, Inc.（US）
Novo Nordisk A/S（Denmark）
Sanofi S.A.（France）
Merck KGaA（Germany）
Genmab A/S（Denmark）
Regeneron Pharmaceuticals, Inc.（US）
Incyte Corporation（US）

Product Code: SQMIG35H2248

Global Monoclonal Antibodies Market size was valued at USD 211 billion in 2022 and is poised to grow from USD 235.27 billion in 2023 to USD 562.03 billion by 2031, growing at a CAGR of 11.5% during the forecast period (2024-2031).

Monoclonal antibodies (mAbs) are antibodies generated from a single cell lineage by cloning a specific white blood cell. These antibodies are utilized in drug development and as treatments for a variety of diseases due to their high specificity and effectiveness. The increasing prevalence of chronic diseases globally is expected to drive significant growth in the monoclonal antibody market in the coming years. Additionally, substantial investments in medical research and development, along with advancements in biotechnology, are anticipated to further enhance the demand for these antibodies. The progress in molecular biology is also expected to contribute positively to the monoclonal antibody market, boosting their sales and application. As monoclonal antibodies find expanding uses across healthcare, pharmaceuticals, and biotechnology sectors, new opportunities are emerging for suppliers and developers in this field. However, the market faces challenges, including high development costs, extended time-to-market, and safety concerns, which may hinder its growth. These factors are likely to remain key considerations as the market evolves.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibodies Market Segmental Analysis

Global Monoclonal Antibodies Market is segmented by Source type, Production Type, Application, End-use, and region. Based on Source type, the market is segmented into Murine, Chimeric, Humanized, and Human. Based on Production Type, the market is segmented into In Vivo, and In Vitro. Based on Application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, and Others. Based on End-use, the market is segmented into Hospitals, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Monoclonal Antibodies Market

The increasing global prevalence of chronic diseases has heightened the need for innovative treatments and therapeutics, leading to greater investments in medical research and development. Monoclonal antibodies are central to this R&D, offering critical solutions for managing a variety of chronic conditions. As a result, the growing reliance on monoclonal antibodies in the development of new therapies is expected to drive further market expansion. This trend suggests that the market for monoclonal antibodies will continue to grow as research progresses and new applications are discovered.

Restraints in the Global Monoclonal Antibodies Market

The development of monoclonal antibodies involves intricate and time-consuming research techniques, contributing to high R&D costs. These substantial expenses are reflected in the final product prices, which can limit market growth. The elevated cost of developing monoclonal antibodies makes the end products expensive, posing a challenge to market expansion. Consequently, the high development costs are a significant factor impacting the overall growth of the monoclonal antibody market.

Market Trends of the Global Monoclonal Antibodies Market

The expiration of patents for monoclonal antibodies presents promising opportunities for the development of biosimilars and biobetters. Companies can focus their research and development efforts on creating biosimilars for well-established monoclonal antibodies whose patents are nearing expiration. By investing in the development of these biosimilars, companies have the potential to capitalize on the market for these products and achieve significant long-term profits. This strategic move can offer substantial financial benefits as the market for original monoclonal antibodies becomes more competitive.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Supply chain Analysis
Case study Analysis
PESTEL Analysis
Regulatory Analysis
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Monoclonal Antibodies Market by Source type

Market Overview
Murine
Chimeric
Humanized
Human

Monoclonal Antibodies Market by Production Type

Market Overview
In Vivo
In Vitro

Monoclonal Antibodies Market by Application

Market Overview
Oncology
Autoimmune Diseases
Infectious Diseases
Neurological Diseases
Others

Monoclonal Antibodies Market by End-use

Market Overview
Hospitals
Specialty Centers
Others

Monoclonal Antibodies Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genmab A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

モノクローナル抗体の市場規模、シェア、成長分析、供給源タイプ別、生産タイプ別、用途別、最終用途別、地域別 - 産業予測、2024年～2031年

Monoclonal Antibodies Market Size, Share, Growth Analysis, By Source Type, By Production Type, By Application, By End-use, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

モノクローナル抗体市場：供給源タイプ別

モノクローナル抗体市場：生産タイプ別

モノクローナル抗体市場：用途別

モノクローナル抗体市場：最終用途別

モノクローナル抗体市場規模：地域別